Cat. No.: HY-W565665

(S)-HPMPA

Customer Review

Based on 1 Customer Validation

(S)-HPMPA is an antiviral agent. (S)-HPMPA can bind to and interfere with viral DNA polymerase activity, thereby inhibiting viral DNA synthesis. (S)-HPMPA can be used for the study of DNA viruses.

For research use only. We do not sell to patients.

Purity: 99.89%
CAS No.: 92999-29-6
Formula: C₉H₁₄N₅O₅P
Molecular Weight:303.21

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

(S)-HPMPA Chemical Structure

CAS No.: 92999-29-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

DNA Polymerase

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	CC₅₀	89.3 μM Compound: HPMPA	Cytotoxicity against african green monkey BSC1 cells Cytotoxicity against african green monkey BSC1 cells	[PMID: 17420214]
BSC-1	EC₅₀	10.2 μM Compound: HPMPA	Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	12.3 μM Compound: HPMPA	Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	15.4 μM Compound: HPMPA	Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
HEL	EC₅₀	0.036 μM Compound: HPMPA	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.08 μM Compound: HPMPA	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.081 μg/mL Compound: (S)-HPMPA	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.11 μg/mL Compound: (S)-HPMPA	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.12 μM Compound: HPMPA	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.17 μM Compound: HPMPA	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.2 μM Compound: HPMPA	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.91 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.2 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.9 μM Compound: HPMPA	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2 μg/mL Compound: (S)-HPMPA	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	2.1 μM Compound: HPMPA	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2.3 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	3.3 μg/mL Compound: (S)-HPMPA	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	6.2 μg/mL Compound: (S)-HPMPA	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL 299	CC₅₀	32 μM Compound: 1b, HPMPA	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HEL 299	EC₅₀	0.5 μM Compound: 1b, HPMPA	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HepG2 2.2.15	CC₅₀	>300 μM Compound: (S)-HPMPA	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay	[PMID: 19398648]
HepG2 2.2.15	EC₅₀	1.2 μM Compound: (S)-HPMPA	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay	[PMID: 19398648]
HFF	CC₅₀	>289 μM Compound: (S)-HPMPA	Cytotoxicity against HFF cell Cytotoxicity against HFF cell	[PMID: 16539388]
HFF	CC₅₀	>289 μM Compound: (S)-HPMPA	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	EC₅₀	2.7 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	2.7 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	4 μM Compound: (S)-HPMPA	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	4 μM Compound: (S)-HPMPA	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	6.5 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	IC₅₀	0.41 μM Compound: 1, (S)-HPMPA	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	100 μM Compound: 1, (S)-HPMPA	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	2 μM Compound: 1, (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	35 μM Compound: 1, (S)-HPMPA	Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	4 μM Compound: 1, (S)-HPMPA	Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
Huh-7	CC₅₀	>100 μM Compound: (S)-HPMPA	Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay	[PMID: 19289518]
Huh-7	EC₅₀	>100 μM Compound: (S)-HPMPA	Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization	[PMID: 19289518]
KB	IC₅₀	>100 μM Compound: 1, (S)-HPMPA	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis	[PMID: 21812420]

In Vitro

(S)-HPMPApp is a good substrate for vaccinia DNA polymerase, readily incorporating into the DNA strand without causing strand termination; instead, it exerts its inhibitory effect by inhibiting 3'-to-5' exonuclease activity and blocking template strand elongation^[1].
(S)-HPMPA (1-100 μg/mL, 24-72 h) can effectively inhibit viral replication in primary rabbit kidney cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 92999-29-6
Appearance Solid
Molecular Weight 303.21
Formula C₉H₁₄N₅O₅P
Color White to off-white
SMILES

O=P(O)(O)CO[C@H](CO)CN1C2=NC=NC(N)=C2N=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H₂O : 62.5 mg/mL (206.13 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2980 mL

16.4902 mL

32.9804 mL

5 mM

0.6596 mL

3.2980 mL

6.5961 mL

10 mM

0.3298 mL

1.6490 mL

3.2980 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 2009 May;82(2):A84-98. [Content Brief]

[2]. De Clercq E, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2-8;323(6087):464-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	3.2980 mL	16.4902 mL	32.9804 mL	82.4511 mL
	5 mM	0.6596 mL	3.2980 mL	6.5961 mL	16.4902 mL
	10 mM	0.3298 mL	1.6490 mL	3.2980 mL	8.2451 mL
	15 mM	0.2199 mL	1.0993 mL	2.1987 mL	5.4967 mL
	20 mM	0.1649 mL	0.8245 mL	1.6490 mL	4.1226 mL
	25 mM	0.1319 mL	0.6596 mL	1.3192 mL	3.2980 mL
	30 mM	0.1099 mL	0.5497 mL	1.0993 mL	2.7484 mL
	40 mM	0.0825 mL	0.4123 mL	0.8245 mL	2.0613 mL
	50 mM	0.0660 mL	0.3298 mL	0.6596 mL	1.6490 mL
	60 mM	0.0550 mL	0.2748 mL	0.5497 mL	1.3742 mL
	80 mM	0.0412 mL	0.2061 mL	0.4123 mL	1.0306 mL
	100 mM	0.0330 mL	0.1649 mL	0.3298 mL	0.8245 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

(S)-HPMPA

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

MCE Bioactive Compound Library

High-Throughput Bioactive Compound Library

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(S)-HPMPA

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

MCE Bioactive Compound Library

High-Throughput Bioactive Compound Library

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(S)-HPMPA Related Classifications

HY-W565665 Related Classifications